Cargando…

Juvenile hemochromatosis: HAMP mutation and severe iron overload treated with phlebotomies and deferasirox

Juvenile hemochromatosis (JH) is a rare condition classified as an autosomal recessive disorder that leads to severe iron absorption. JH usually affects people under the age of 30 and presents symptoms such as chronic liver damage, hypogonadotropic hypogonadism, cardiac diseases and endocrine dysfun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lescano, Manuel A, Tavares, Letícia C, Santos, Paulo C J L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649000/ https://www.ncbi.nlm.nih.gov/pubmed/29085829 http://dx.doi.org/10.12998/wjcc.v5.i10.381

Ejemplares similares

A Phase 1/2, Dose-Escalation Trial of Deferasirox for the Treatment of Iron Overload in HFE-Related Hereditary Hemochromatosis
por: Phatak, Pradyumna, et al.
Publicado: (2010)

Phlebotomy increases cadmium uptake in hemochromatosis.
por: Akesson, A, et al.
Publicado: (2000)

Update on the use of deferasirox in the management of iron overload
por: Taher, Ali, et al.
Publicado: (2009)

Educational Case: Iron Overload and Hemochromatosis
por: Borowitz, Michael J., et al.
Publicado: (2018)

Atypical juvenile hereditary hemochromatosis onset with positive pancreatic islet autoantibodies diabetes caused by novel mutations in HAMP and overall clinical management
por: Wu, Hui‐Xuan, et al.
Publicado: (2020)

Dysmetabolic Hyperferritinemia: All Iron Overload Is Not Hemochromatosis
por: Makker, Jasbir, et al.
Publicado: (2015)

Iron Chelation Therapy with Deferasirox in the Management of Iron Overload in Primary Myelofibrosis
por: Elli, Elena Maria, et al.
Publicado: (2014)

Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
por: Wu, Dijiong, et al.
Publicado: (2018)

Juvenile Hemochromatosis: Rheumatic Manifestations of 2 Sisters Responding to Deferasirox Treatment. A Case Series and Literature Review
por: Alqanatish, Jubran, et al.
Publicado: (2021)

Histologic Lesions of Porto-Sinusoidal Vascular Disease Following Phlebotomy in Hemochromatosis
por: El Jabbour, Tony, et al.
Publicado: (2020)

A farewell to phlebotomy—use of placenta-derived drugs Laennec and Porcine for improving hereditary hemochromatosis without phlebotomy: a case report
por: Hamada, Yuki, et al.
Publicado: (2022)

Protective effects of deferasirox and N-acetyl-L-cysteine on iron overload-injured bone marrow
por: Shen, J.C., et al.
Publicado: (2017)

Testing and Management of Iron Overload After Genetic Screening–Identified Hemochromatosis
por: Savatt, Juliann M., et al.
Publicado: (2023)

Exjade® (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion
por: Cappellini, Maria Domenica
Publicado: (2007)

Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia
por: Hagag, Adel A., et al.
Publicado: (2013)

Efficacy and Safety of Combined Deferiprone and Deferasirox in Iron-Overloaded Patients: A Systematic Review
por: Salem, Ahmed, et al.
Publicado: (2023)

A predictive model for estimating the number of erythrocytapheresis or phlebotomy treatments for patients with naïve hereditary hemochromatosis
por: Rombout‐Sestrienkova, Eva, et al.
Publicado: (2020)

Management of Iron Overload in Resource Poor Nations: A Systematic Review of Phlebotomy and Natural Chelators
por: Orisakwe, Orish Ebere, et al.
Publicado: (2020)

Leukocyte telomere length is associated with iron overload in male adults with hereditary hemochromatosis
por: Martín, Maximilino, et al.
Publicado: (2020)

Dietary Iron Overload and Hfe(−/−) Related Hemochromatosis Alter Hepatic Mitochondrial Function
por: Fischer, Christine, et al.
Publicado: (2021)

Predicting serum ferritin levels in patients with iron overload treated with the film‐coated tablet of deferasirox during the ECLIPSE study
por: Taher, Ali T., et al.
Publicado: (2018)

Patients with hereditary hemochromatosis reach safe range of transferrin saturation sooner with erythrocytaphereses than with phlebotomies
por: Rombout‐Sestrienkova, Eva, et al.
Publicado: (2021)

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study
por: Taher, Ali, et al.
Publicado: (2009)

Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major
por: Karami, Hossein, et al.
Publicado: (2017)

Frequency of Hereditary Hemochromatosis (HFE) Gene Mutations in Egyptian Beta Thalassemia Patients and its Relation to Iron Overload
por: Enein, Azza Aboul, et al.
Publicado: (2016)

New thiazolidinones reduce iron overload in mouse models of hereditary hemochromatosis and β-thalassemia
por: Liu, Jing, et al.
Publicado: (2019)

Comprehensive analysis of HFE gene in hereditary hemochromatosis and in diseases associated with acquired iron overload
por: de Campos, Wagner Narciso, et al.
Publicado: (2019)

Iron overload exacerbates age-associated cardiac hypertrophy in a mouse model of hemochromatosis
por: Sukumaran, Abitha, et al.
Publicado: (2017)

Despite Genetic Iron Overload, Hfe‐Hemochromatosis Mice Do Not Show Bone Loss
por: Wagner, Alessa, et al.
Publicado: (2019)

Effect of standard phlebotomy on myocardial and hepatic iron levels in newly diagnosed cardiac asymptomatic hereditary hemochromatosis subjects with C282Y homozygosity
por: Shizukuda, Yukitaka, et al.
Publicado: (2023)

Iron Chelation Therapy with Deferasirox Results in Improvement of Liver Enzyme Level in Patients with Iron Overload-Associated Liver Dysfunction
por: Miura, Yasuo, et al.
Publicado: (2010)

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease
por: Vichinsky, Elliott, et al.
Publicado: (2007)

Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with β-thalassemia major
por: Pathare, Anil, et al.
Publicado: (2009)

Hamp1 but not Hamp2 regulates ferroportin in fish with two functionally distinct hepcidin types
por: Neves, João V., et al.
Publicado: (2017)

Secondary hemochromatosis as a result of acute transfusion-induced iron overload in a burn patient
por: Amatto, Michael, et al.
Publicado: (2016)

Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent β-thalassemia
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2017)

Comment on: Hemochromatosis (HFE) gene mutations (H63D and C282Y) and iron overload in beta-thalassemia major
por: Yasri, Sora
Publicado: (2019)

Iron overload phenotypes and HFE genotypes in white hemochromatosis and iron overload screening study participants without HFE p.C282Y/p.C282Y
por: Barton, James C., et al.
Publicado: (2022)

Managing Genetic Hemochromatosis: An Overview of Dietary Measures, Which May Reduce Intestinal Iron Absorption in Persons With Iron Overload
por: Milman, Nils Thorm
Publicado: (2021)

Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload
por: Alavi, Samin, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jr1qoqttate31e6uh9is8fpafq